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What causes many cancer patients to die of tumor-related p r o b l e m s -
such as a respiratory tract infection, a urinary obstruction, or malnutri-
tion—rather than of the tumor itself? Scientists at BUSM are conducting 
research they hope will answer this question. See story on page 3. 
BUSM researchers 
study benefits 
of exercise in 
treating diabetes 
Studies by researchers at Boston 
University School of Medicine could 
lead many individuals with the matu-
rity onset form (Type II) of diabetes 
mellitus literally to run for their lives. 
While most everyone feels better 
after exercise—whether it's riding a 
bicycle to work, swimming a few laps 
at the pool or just going for a walk— 
BUSM researchers, working in con-
junction with researchers at New Jer-
sey College of Medicine, are gather-
ing new information about how 
exercise can help control this com-
mon impairment of the body's ability 
to control blood sugar. 
Eighty-five percent of all diabetics 
in the United States have Type II 
diabetes, and most of them are 
treated with oral drugs and special 
diets. The remaining 15 percent have 
the more severe juvenile-onset (Type 
I) form of diabetes, and must control 
the disease with injections of insulin, 
the body's own sugar-regulating hor-
mone. 
Type II diabetics, who do not 
require insulin injections, usually are 
able to live normal lives by control-
ling their diet and keeping their 
weight down. However, they are at 
high risk for developing premature 
atherosclerosis in coronary, periph-
eral and cerebral arteries, which can 
continued on page 2 
Neil B. Ruderman, M.D., D.Phll., conducts research on a rat as part of his studies on the effects 
of exercises on diabetics. (Photo by Lewis Glass, Educational Media, BUSM) 
Scientists explore cells' Inner workings 
to determine causes of abnormalities 
From the moment of conception to 
the birth of a child, billions of cells 
are created in the womb. Early in 
development, these cells multiply at 
a tremendous rate while moving in 
the embryo. At a certain point, the 
nulcei of these cells "decide" what 
type of cells they will be (nerve cells, 
blood cells, etc.), and where in the 
body they will be located. 
What triggers this "decision?" Why, 
for instance, do two seemingly simi-
lar cells formed at the same instant 
in the embryonic nervous system 
develop differently and move in sep-
arate directions—one to become a 
neuron in the brain, another to 
become one of thousands of cells 
that form nerve endings in the 
tongue? 
Researchers at Boston University 
School of Medicine are working to 
answer such questions about cell 
continued on page 5 
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Exercise In diabetes... 
continued from page 1 
lead to heart attacks, strokes and 
gangrene. For example, diabetic men 
and women are two to three times 
more likely to have a stroke, and dia-
betic women are seven to eight 
times more likely to have a heart 
attack, than comparable people in 
the general population. 
Results from early investigations 
conducted by researchers under the 
direction of Neil B. Ruderman, M.D., 
D.Phil., a professor of medicine and 
chief of the Division of Diabetes and 
Metabolism of the Department of 
Medicine at BUSM, suggest that a 
simple program of regular exercise 
may be useful in preventing some of 
the complications experienced by 
Type II diabetics. 
"While we don't really know if exer-
cise slows the development of cardi-
ovascular disease in the diabetic, we 
do know there are risk factors for 
atherosclerotic disease that change 
in the right direction when a non-dia-
betic exercises. These factors 
include raised plasma cholesterol, 
insulin, and triglycerides, and high 
blood pressure," explained Ruder-
man. They also include low fibrino-
lytic activity—a reduced ability to 
break down blood clots in the circula-
tory system—which often is a prob-
lem in diabetics. 
Ruderman began his studies on 
the role of exercise in diabetes about 
four years ago, when animal studies 
suggested that the ability of muscle 
to metabolize glucose—the form of 
sugar used by the body for energy— 
is temporarily improved following 
bouts of exercise. Because impaired 
glucose tolerance is a fundamental 
problem that could contribute to the 
vascular complications in diabetics, 
and because physical exertion helps 
maintain a healthy cardiovascular 
system, Ruderman and his col-
league, former BUSM researcher 
Stephen H. Schneider, M.D., now at 
the New Jersey College of Medicine, 
Subjects in study conducted by Neii B. 
Ruderman, M.D., D.Phii., exercise 30 minutes 
a day, three times a week for six weeks. 
(Photo by Lewis Giass, Educationai Media, 
BUSM) 
set up a three-year study to test their 
hypothesis that exercise would be 
beneficial in treating Type II diabetes 
in humans. The research is funded 
by grants from the National Institute 
of Arthritis, Diabetes and Digestive 
and Kidney Diseases. 
In the study, patients exercise 30 
minutes a day, three times a week 
for six weeks. The patients, mostly 
Type II diabetic males between 40 
and 60 years old (the diabetic group 
most at risk for coronary disease), 
maintain their normal diet and keep a 
diary of the foods they eat. In this 
way the researchers can detect any 
dietary changes that might influence 
the results. Patients above the age 
of 40 with diabetes for more than 10 
years or with a family history of heart 
disease are required to take an exer-
cise electrocardiogram before start-
ing the program. Those foUnd to 
have existing heart disease are care-
fully supervised. 
Patients in the study engage in 
such endurance exercises as run-
ning, cycling and swimming. In the 
early stages of the investigation, 
however, patients worked out on a 
bicycle ergometer, a standing bicycle 
with a device that measures the 
amount of work performed. At 
selected intervals the research staff 
analyzes the patients' blood. 
"Our first clue that the exercise 
was improving glucose tolerance was 
the measure of the patients' hemo-
globin A -1 , hemoglobin that has 
sugar bound to it. We found that it 
went down," explained Ruderman, 
"suggesting that the patients' aver-
age blood sugar level during the six 
weeks of exercise was lower than it 
had been previously." 
Guided by this initial evidence, the 
researchers administered glucose 
tolerance tests at 12 hours and at 72 
hours following exercise. They dis-
covered that in every patient, toler-
ance was better at 12 hours. "And, in 
about half of the patients, it was 
much better," noted Ruderman. 
"We reasoned that the improve-
ment in glucose tolerance after exer-
cise is a result of an increase in use 
of sugar by the muscle as it repletes 
its stores of glycogen, the carbohy-
drate form in which muscles store 
sugar," explained Ruderman. "Exer-
cising muscles use their glycogen for 
energy, and for reasons we do not 
yet understand, following exercise 
there is an increase in insulin sensi-
tivity as muscle uses blood sugar to 
rebuild its glycogen. This results in 
an improvement in glucose toler-
ance," said the investigator. 
"Another finding is that exercise 
lowers plasma triglycerides and 
increases fibrinolytic activity. In some 
patients blood pressure, plasma cho-
lesterol and insulin also may 
decrease. By virtue of these many 
effects on risk factors, we hope exer-
cise will retard the development of 
atherosclerosis in diabetics," said the 
investigator. 
About 60 patients currently are in 
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Researchers eye metabolic factors 
causing death in cancer patients 
the study, and a total of 120 patients 
have been entered since its begin-
ning. Data has been analyzed on 
about 25 patients. 
Ruderman said future research will 
be aimed at identifying potential dia-
betics and those most likely to bene-
fit from an exercise program, be-
cause diabetes and its vascular com-
plications may be easier to prevent 
than to treat. "Hopefully, genetic 
markers will soon be available to 
allow us to do this," he said. 
While Ruderman's research still is 
under way, he recommends that pre-
viously inactive Type II diabetics 
undertake exercise programs only 
after consulting a physician. He feels 
that substantial benefit may result 
from exercise three to five times a 
week, for about half an hour a day. 
Swimming, cycling, running, tennis 
and similar activities are among the 
best exercises for such a program, 
he noted. "Even walking or garden-
ing might be suitable, although not 
as good," he said. 
"You don't have to be a marathon 
runner who does 100 miles a week. 
Indeed, beyond seven to 10 miles a 
week we find an increasing incidence 
of orthopedic problems of the ankles, 
knees and hips," the researcher said. 
"There's a lot to be learned," said 
Ruderman. "Which people will bene-
fit, how much they will benefit, what 
the precise exercise regimen should 
be and which factors we should look 
for to determine progress all are 
questions that remain to be 
answered." 
—Steve Stiles 
Suggested Further Readings 
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1: 89-92, January 1979. 
2. Richter, E.A., et al: Diabetes and exercise. 
Amer. J. Med. 70: 201-208, January 1981. 
3. Richter, E.A., et al: Muscle glucose metab-
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Increased sensitivity to insulin. J. Clin. 
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One of the questions that has long 
perplexed researchers and clinicians 
alike is how cancer actually harms 
the patient. In many cases, the 
patient dies of a tumor-related prob-
lem—a respiratory tract infection, or 
urinary- or gastrointestinal-tract 
obstruction. Many patients eventually 
suffer from cachexia, the malnutrition 
and physical wasting usually associ-
ated with chronic disease. This prob-
lem is the result of changes within 
the patient's metabolic system, 
caused by the uncontrollable growth 
of cancer cells. 
A team of researchers headed by 
Dennis F. Devereux, M.D., director of 
the Surgical Oncology Research 
Laboratory at Boston University 
School of Medicine, is working to 
identify possible biochemical factors 
in tumors that contribute to these 
metabolic defects. 
"The tumor itself often isn't large 
enough to kill a patient. It's all the 
metabolic changes the tumor causes 
within the host that eventually cause 
death," said Devereux, who also is 
director of surgical oncology at Bos-
ton City Hospital, an assistant pro-
fessor of surgery at BUSM, and a 
member of the School's Hubert H. 
Humphrey Cancer Research Center. 
Devereux began studying the 
problem of the host (or body's) 
response to tumors in 1976 while 
working at the National Cancer Insti-
tute in Bethesda, Md. He recently 
discovered that the blood of rats 
bearing fibro-sarcomas—small 
tumors found in soft tissue, muscles, 
connective tissue and blood ves-
sels—had larger-than-normal 
amounts of triglycerides, a type of 
lipid (fat). The amount of lipids pres-
ent directly corresponded to the size 
of the tumors the rats were carrying. 
He found that this condition, called 
hypertriglyceridemia, could be 
reversed only partially with injections 
of glucose and insulin. 
According to Devereux, these tests 
also have shown that fibro-sarcoma 
cells use large quantities of glucose 
for growth. As a result, the host's 
blood has lower-than-normal levels 
of the glucose and insulin, which are 
necessary for host-cell maintenance. 
In an effort to combat these prob-
lems, Devereux and his research 
team—Trevor Redgrave, M.D., an 
associate research professor of med-
icine and an associate professor of 
physiology at BUSM; David Hol-
lander, M.D., BUSM '81, a teaching 
fellow in medicine; and Henry 
Hoppe, Ph.D., a research associate 
in the Medical Oncology Group at 
University Hospital—planned a diet 
high in additional fats and found that 
tumor-bearing rats could not metabo-
lize the exogenous (added) fats. 
"For years, cancer patients have 
been hyperalimented, that is, given 
additional lipids and proteins to com-
bat cachexia. Now we're learning 
that it may not be the best combina-
tion for cancer patients," Devereux 
explained. 
Hypertriglyceridemia also has been 
shown in previous studies to sup-
press the function of lymphocytes, 
Devereux said. Lymphocytes are 
white blood cells that are important 
to the host immune system in fight-
ing infection and recognizing dis-
ease. However, when excess lipids 
are present in the bloodstream, the 
lymphocytes are unable to recognize 
the antigens they normally should 
recognize and, therefore, are unable 
to respond appropriately. This infor-
mation may explain why cancer 
patients often become more suscep-
tible to other types of illness and 
succumb to infection, according to 
Devereux. 
Devereux and his co-investigators, 
whose work is funded by the Hum-
phrey Cancer Research Center, have 
been working on ways to identify a 
possible factor in the blood serum of 
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tumor-bearing rats that might 
account for the system's inability to 
return blood-lipid levels to normal. 
The basic problem is that cachexia 
in cancer patients is a wasting-away 
syndrome in which the patients 
become malnourished, the re-
searcher said. Because the body 
contains only three major energy 
sources—sugars, lipids and pro-
teins—losing more of one than of the 
others may deplete the host of fuel 
for energy. 
Since the tumor is using up exces-
sive amounts of carbohydrates for 
growth, the host has no available 
carbohydrates to use. Therefore, the 
host apparently mobilizes all of its fat 
for energy supplementation. Once 
the host runs out of fat, it begins 
using protein, thereby eventually 
causing cachexia, tissue-wasting, 
and ultimately, death. 
"We have identified a factor in the 
sera of tumor-bearing animals that is 
responsible for this massive fat mobi-
lization," Devereux said. This factor 
may be responsible for the irrevers-
ible fat-losing state noted in cancer 
patients. This, in turn, compounds 
cachexia. 
"We haven't characterized the fac-
tor yet and we don't know what its 
exact components and constituents 
are, but we have identified its pres-
ence," he said. 
In addition to these studies, Dever-
eux and his research associates are 
working to develop new methods to 
treat cancer patients without worsen-
ing the already malfunctioning 
metabolism. They also are studying 
the mechanisms of glucose and 
tumor growth. Though their work in 
these areas still is in the early 
stages, the researchers said it looks 
promising. 
As part of the tumor-growth stud-
ies, the researchers work with 2-milli-
meter fibro-sarcomas that have been 
surgically implanted in rats. They 
have found that they have been able 
to temporarily slow down tumor 
growth, both within the rat and in a 
tissue-culture setting, by injecting 
anti-neoplastic (anti-tumor) agents 
that suppress cell division. 
The agents the researchers have 
been using are 2-deoxy-glucose, a 
non-energy yielding glucose ana-
logue (an inactive compound similar 
to glucose but that has the opposite 
metabolic effects), and a drug called 
Ara-C, a sugar-like anti-neoplastic 
agent that the tumor is unable to 
metabolize. "While we have not 
been able to prevent tumor growth 
completely," said Devereux, "the 
agents have been relatively effective 
in slowing down the usually rapid 
growth of the tumor." 
These agents are effective 
because the tumor cells use such 
large amounts of glucose that they 
"mistakenly" pick up these non-
energy yielding compounds. The 
tumor cells, therefore, are not able to 
reproduce themselves as rapidly. 
"All of this relates to the metabolic 
activity of the tumor itself," Devereux 
explained. "If the tumor were not this 
metabolically active—for example, 
picking up the sugar—then we 
couldn't 'confuse' it by giving it a 
'poison' sugar. But it just happens 
that the sarcoma cell lives off the 
sugar and subsequently can be 
tricked into trying to metabolize 
sugar-like anti-neoplastic com-
pounds, like 2-deoxy-glucose and 
Ara-C." 
The decrease in the tumor growth 
rate, however, is only temporary. 
Therefore, Devereux said, the next 
step in the research effort is to use 
combinations of the 2-deoxy-glucose 
and Ara-C to see if the combined 
effects are great enough to prevent 
growth entirely. 
"We're not dealing with a 'miracle 
cure' for cancer," Devereux said with 
cautious optimism. "But perhaps in 
time, we can use this as a treatment 
method in conjunction with other 
forms of treatment—like chemother-
apy, radiation and surgery—and wipe 
out these tumors altogether." 
—Heidi Paui 
Suggested Further Readings 
1. Devereux, D., et al: The effect of tumor 
bearing and removal on lipid metabolism in 
the rat. Surg. Forum 33: 406-408, 1982. 
2. Spiegel, R.J., et al: Plasma lipid alterations 
in leukemia and lymphoma. Am. J. Med. 
72: 775, 1982. 
Dennis F. Devereux, M.D., right, and research associate David A. Hollander, M.D., conduct 
laboratory animal research. (Photo by Lewis Glass, Educational Media, BUSM) 
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Inner workings of cells... 
continued from page 1 
development, specifically those sur-
rounding the development of the 
cells in the nervous system. The 
answers someday may help scien-
tists solve the mysteries of such con-
ditions as Alzheimer's disease, Par-
kinson's disease and cancer, and to 
better treat—and perhaps cure— 
patients with spinal-cord injuries. 
"The more we learn about the ner-
vous system through this basic 
research, the better chance we're 
going to have of understanding what 
goes wrong with this system," said 
Stephen R. Farmer, Ph.D., who has 
been studying cell development in 
the nervous system for the past 
seven years. 
"The next milestone, or level of 
complexity, that scientists want to 
understand is the brain. There are 
many, many disorders that exist 
within the nervous system that we 
don't understand," said Farmer, an 
assistant professor of biochemistry 
who is working in the Hubert H. 
Humphrey Cancer Research Center. 
The Humphrey Center is located in 
the School's new Centers for 
Advancement in Health and Medi-
cine. 
A cell is made up of a semi-
permeable membrane surrounding 
the intracellular matrix, or the cell's 
skeleton. Inside of this structure is 
the nucleus, where the cell's genetic 
material is located. This genetic-cod-
ing material in the developing cell 
has the capability of making that cell 
any one of several different types. 
Developing cells in the womb that 
eventually will make up the nervous 
system are located in a particular 
region of the embryo called the 
neural crest. Researchers are rela-
tively sure that the way the cells of 
the neural crest develop is depen-
dent upon the surfaces to which the 
cells find themselves attached, 
according to Farmer. 
"The cell responds to the 'signals' 
of its physical environment by 'turn-
ing on' particular sets of genes. This 
eventually determines the particular 
cell-type that arises," said Farmer. 
Farmer is working on several lev-
els to understand this development 
phenomenon. On one level, he is 
studying the specific effects of these 
external signals on the genes nestled 
in the developing cell nucleus. 
On another level, using experi-
ments performed on cells grown in 
lab cultures. Farmer is altering the 
surfaces on which the cells rest to 
determine what effect this has on the 
development of the cells. 
"We can develop cell-culture 
experiments where we can isolate 
nerve cells and grow them in cul-
tures," explained Farmer. "We can 
change their physical environment 
(what the cell "sits on") and then, 
using molecular biology and recombi-
nant DNA techniques (measuring the 
activity of specific genes), we can 
analyze the effect that change has 
on the gene coding for nerve-specific 
functions." 
Farmer also is trying to determine 
exactly how the cells' nuclei receive 
the signals from the surfaces to 
which they are attached. 
"The cell knows what it's sitting on, 
but we don't know how it knows 
that," said Farmer. 
The signals probably are transmit-
ted physically from the extracellular 
matrix (the surface on which the cell 
rests) to the nucleus of the cell 
through the intracellular matrix, said 
Farmer. 
In an effort to prove whether or not 
this is the case, he is working to alter 
with drugs the skeleton of the cells 
themselves to stimulate changes in 
the cell's development without 
changing the surfaces on which the 
cells sit. He will determine if this will 
elicit the same responses in the cell 
that occur when the surfaces are 
changed. 
"This will enable us to see if the 
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internal skeleton is in fact the means 
of transmitting those signals to the 
nucleus," he said. 
Farmer's research already has 
enabled him to define the genes that 
activate specific types of nerve-cell 
proteins. "We've been able to clone 
those genes using recombinant DNA 
technology and show that the pro-
duction of proteins coded for by one 
of those genes does in fact respond 
to specific drug-induced changes in 
the cell skeleton," he said. 
"Now, I'm trying to show that the 
gene also responds to changes in 
the shape of the nerve cell, brought 
about by growth on different sur-
faces," said Farmer. 
Farmer hopes his basic research 
someday will aid in the treatment of 
several different types of disorders. 
One of the more interesting possible 
results of his work would be in the 
area of treatment of spinal-cord inju-
ries. 
"The problem with nerve tissue is 
that it doesn't regenerate itself as 
easily as other tissues," said Farmer. 
"There are many situations in which 
spinal-cord injuries and other types 
of lesions in the nervous system 
could be corrected with transplanted 
regions of nervous tissue." 
"If we can understand more about 
what controls the growth of nerve 
cells, and if we could somehow con-
trol the growth of nerve cells, then 
there may be a chance that we will 
someday be able to do transplanta-
tion-type experiments on the nervous 
system," he explained. 
Noting that such experiments prob-
ably will not be undertaken for many 
years. Farmer said if scientists can 
transplant early embryonic nerve 
cells that still have the potential to 
develop, and if they know what is 
required in that environment to stim-
ulate that growth, then "it is not 
unrealistic to think that we will be 
able to do that sort of experiment." 
Other areas in which this type of 
research may be able to help in the 
future include the understanding and 
treatment of such nervous system 
diseases as Parkinson's, Hunting-
ton's and Alzheimer's diseases. 
"Cell development and cancer are 
very much related," said Farmer. 
"The more we understand about nor-
mal development and what these 
particular cells depend upon to bring 
about that normal development, the 
more we will understand about what 
goes wrong during malignant trans-
formation." 
He said that a prevalent idea 
among cancer researchers is that 
cancer cells are merely cells that 
revert back to an earlier develop-
mental stage, a stage of very active 
growth and mobility. 
"Cancers within the nervous sys-
tem, neuroblastomas (tumors in the 
nerve cells), are quite a problem in 
very young children...By understand-
ing normal growth, we hope to be 
able to understand more about the 
production of cells in the nervous 
system that become malignant," said 
Farmer. 
To this end. Farmer is working 
with co-researchers Richard M. 
Niles, Ph.D., an associate professor 
of biochemistry, and Ellen Berkowitz, 
Ph.D., an assistant professor of bio-
chemistry. Their work is funded by 
the National Institutes of Health, and 
they currently are seeking more 
funds to expand their work. 
"The more we understand basic 
mechanisms of growth and develop-
ment of nerve cells, the better 
chance we will have of being able to 
do these new types of experiments 
and understand and treat the many 
diseases of the nervous system," 
said Farmer. 
—Paul D. Vaskas 
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